Primary esophageal sarcomas

Primary esophageal sarcomas are extremely rare mesenchymal neoplasms arising from the connective tissues of the esophageal wall or from interstitial cells of Cajal, and they constitute a distinct category from esophageal carcinomas in both biology and natural history. At this site, the histologic spectrum is heterogeneous and mainly includes esophageal gastrointestinal stromal tumor (GIST), together with even less common forms such as leiomyosarcoma, synovial sarcoma, rhabdomyosarcoma and other neoplasms with vascular or undifferentiated differentiation. Their rarity substantially limits the available evidence, which is often based on small series, and makes early multidisciplinary assessment at centers experienced in sarcomas and esophageal tumors essential.

Clinically, these tumors most often present with progressive dysphagia, a retrosternal foreign-body sensation, pain, weight loss and, in some variants, bleeding and anemia. Presentation may be insidious because many lesions grow as submucosal, sometimes polypoid masses with initially intact overlying mucosa. Consequently, endoscopy may reveal a stricture or protruding lesion without pathognomonic features, and diagnosis requires an appropriate sampling strategy, often supplemented by endoscopic ultrasonography and targeted biopsy techniques to obtain representative tissue.

Definitive diagnosis is pathologic and depends on integration of morphology, immunohistochemistry and, when necessary, molecular profiling, because many entities have highly informative markers or genetic alterations. Treatment is generally multimodal and varies according to histologic type: in GISTs, targeted therapy with tyrosine kinase inhibitors may be decisive, whereas in other sarcomas radical resection, when feasible, remains a cornerstone, with selective use of radiotherapy and chemotherapy according to guidelines for soft-tissue sarcomas and specific subtypes.

The epidemiology of primary esophageal sarcomas is defined by their exceptional rarity. Among esophageal neoplasms as a whole, the mesenchymal component represents only a marginal fraction; within this group, esophageal GIST is the most common subgroup, but it remains rare compared with gastric and small-bowel GISTs. Other histologies, such as leiomyosarcoma and synovial sarcoma, are mainly reported as isolated cases or small series, making it impossible to estimate incidence and geographic distribution accurately.

Demographically, esophageal GISTs tend to affect adults, whereas certain variants such as rhabdomyosarcoma may also occur at a younger age, although they remain exceptional. Tumors arising from the muscularis propria or stroma are often located in the middle or distal esophagus, but distribution is variable and depends on histologic type. Rarity creates a genuine risk of misclassification, particularly with common benign lesions such as esophageal leiomyoma, and requires rigorous diagnostic verification.

The etiologic causes of primary esophageal sarcomas have not been defined. No necessary and sufficient exposures are known to cause disease at this site, and the absence of an established etiology distinguishes these tumors from other gastrointestinal neoplasms with well-characterized environmental determinants. In particular, the classic factors implicated in esophageal carcinomas have no demonstrated causal role in sarcomas.

In the absence of an identified direct cause, attention focuses on risk factors and predisposing conditions that increase the likelihood of developing specific subtypes. For GISTs, certain genetic disorders may be associated with increased susceptibility throughout the gastrointestinal tract, including neurofibromatosis type 1 and syndromes involving alterations in the SDH pathway, although neither has a strong, specific association with the esophageal site. For other soft-tissue sarcomas, inherited syndromes such as Li-Fraumeni syndrome or RB1-related predisposition may increase the overall risk of sarcomas, but esophageal localization remains rare and does not define a predictive profile useful for population interventions.

In summary, rarity limits the definition of robust epidemiologic patterns; etiology remains unknown, whereas predisposing factors are mostly syndromic and nonspecific to the esophagus, with practical implications chiefly for the clinical and genetic assessment of selected cases.

There are no screening programs or population-surveillance strategies for primary esophageal sarcomas because the incidence is too low to make a systematic approach sustainable, and no noninvasive tests with adequate accuracy are available. Although upper gastrointestinal endoscopy is the cornerstone of diagnosis, it cannot be justified as an early-detection tool in the absence of clinical suspicion because of the unfavorable balance between diagnostic yield and procedural costs, risks and organizational impact.

In clinical practice, early diagnosis depends on recognizing alarm features that warrant endoscopy, including progressive dysphagia, odynophagia, unintentional weight loss, gastrointestinal bleeding, iron-deficiency anemia or persistent retrosternal pain. In these settings, endoscopy is not performed as sarcoma-specific screening but as an appropriate evaluation of potentially organic symptoms, during which a submucosal lesion or intraluminal mass may be identified and sampled.

A separate issue concerns people with syndromes predisposing to GISTs or other mesenchymal tumors. Even in these patients, no universally standardized protocols focus on the esophageal site; when surveillance is performed, it is generally directed at the overall risk of gastrointestinal tumors and must be individualized according to age, clinical history, phenotype and the availability of specialist programs.

Overall, the most rational strategy remains symptom-guided diagnosis, with timely access to endoscopy and, when indicated, endoscopic ultrasonography and staging imaging, while avoiding generalized pathways that would lack both sustainability and evidence of efficacy.

The biology of primary esophageal sarcomas is determined decisively by histologic type and, in most cases, reflects the characteristics of their soft-tissue or gastrointestinal mesenchymal counterparts. The most relevant group is represented by esophageal GISTs, neoplasms derived from interstitial cells of Cajal or related precursors and driven, in most cases, by activating tyrosine kinase alterations. Mutations in KIT and PDGFRA are the best-known drivers, whereas a proportion of tumors are characterized by alternative mechanisms, including defects in the SDH pathway and rare rearrangements. This pathogenetic profile has direct implications because it determines sensitivity and resistance to tyrosine kinase inhibitors and guides treatment selection in advanced disease.

Alongside GISTs, esophageal leiomyosarcomas arise from smooth-muscle differentiation and often show genomic complexity with multiple alterations, analogous to leiomyosarcomas at other sites. Malignant transformation occurs in a biological context distinct from that of stromal tumors, with infiltrative behavior and hematogenous metastatic potential. Distinction from benign lesions, particularly leiomyoma, requires careful assessment of atypia, mitoses, necrosis, infiltrative growth and, when necessary, immunohistochemical and molecular support.

An especially noteworthy, although extremely rare, subtype is esophageal synovial sarcoma, which is defined by a highly characteristic molecular event: an SS18 rearrangement involving SSX genes. This genetic signature permits a robust diagnosis in tumors that may mimic other spindle-cell neoplasms. Esophageal rhabdomyosarcoma, which is even more exceptional, falls within the spectrum of sarcomas with skeletal-muscle differentiation, with biologically distinct subtypes and often aggressive behavior.

Biological drivers and distinguishing features of the main subtypes

• GIST: tyrosine kinase activation through KIT or PDGFRA mutations, or alternative profiles such as defects in the SDH pathway, with predictive implications for treatment.
• Synovial sarcoma: SS18-SSX rearrangement as a highly informative molecular diagnostic marker.
• Leiomyosarcoma: smooth-muscle phenotype with greater genomic complexity and infiltrative behavior.
• Rhabdomyosarcoma: skeletal-muscle differentiation with biologically distinct subtypes and variable aggressiveness.

Histologically, esophageal sarcomas may present as submucosal or intramural masses with polypoid endoluminal growth or an infiltrative component within the wall. In GISTs, morphology may be spindle-cell, epithelioid or mixed, with variable cellularity and stromal sclerosis; leiomyosarcomas predominantly contain bundles of spindle cells with atypia and mitoses; synovial sarcoma may contain spindle-cell patterns together with more epithelioid areas depending on the variant. Assessment of necrosis, mitotic index and invasion is crucial for prognostic classification.

Immunohistochemistry is often decisive. GISTs typically express KIT (CD117) and DOG1, with variable CD34 expression, whereas leiomyosarcomas express smooth-muscle markers such as SMA and desmin. In synovial sarcoma, in addition to supportive markers, molecular confirmation of the rearrangement is essential in equivocal cases. Overall pathogenesis is therefore not uniform: it derives from the interaction among the cell of origin, molecular drivers and the esophageal microenvironment, producing clinical outcomes ranging from slow-growing but recurrent tumors to highly aggressive neoplasms with early metastasis.

The clinical manifestations of primary esophageal sarcomas are mostly nonspecific and related to the degree of obstruction, mucosal ulceration and nutritional impairment. Progressive dysphagia is the most common symptom and may begin with solids before involving liquids, particularly when the mass has a substantial intraluminal component or causes extrinsic narrowing. Odynophagia and retrosternal pain may occur when the wall is ulcerated or infiltrated.

Weight loss reflects both reduced intake because of dysphagia and the systemic mechanisms of aggressive neoplasms and may be accompanied by fatigue and reduced performance status. Regurgitation of undigested food, excessive salivation and postprandial cough may indicate esophageal stasis and aspiration risk. In some presentations, especially with ulcerated lesions, hematemesis, melena or occult bleeding with anemia may occur; this may be more evident in highly vascular tumors or those with superficial necrosis.

In advanced disease, the clinical picture may include signs of metastatic spread that vary according to histologic type. GISTs and leiomyosarcomas tend to metastasize preferentially through the bloodstream, with possible hepatic or pulmonary sites, whereas some subtypes may have different patterns. Compression of mediastinal structures, fistulization to the airways and infectious complications are rare but clinically relevant, particularly in locally advanced disease.

Clinical presentations that most often lead to endoscopy and imaging

• Progressive dysphagia, odynophagia and persistent retrosternal pain.
• Unintentional weight loss and a substantial reduction in food intake.
• Regurgitation, esophageal stasis and respiratory symptoms caused by aspiration.
• Gastrointestinal bleeding or unexplained iron-deficiency anemia.
• Signs or symptoms compatible with metastatic disease, according to the clinical context.

Physical examination findings may be limited in the early stages; with progression, signs of malnutrition, dehydration, pallor and loss of muscle mass may emerge. Clinical evaluation must always include nutritional status and aspiration risk because these factors influence tolerance of diagnostic procedures and access to complex treatment strategies.

The diagnostic work-up for primary esophageal sarcomas begins with suspicion of organic esophageal disease in the presence of dysphagia, weight loss, bleeding or persistent pain and proceeds with the aim of obtaining an accurate histologic diagnosis and a complete definition of disease extent. The first key investigation is upper gastrointestinal endoscopy, which can identify strictures, intraluminal masses or submucosal lesions; however, the endoscopic appearance rarely indicates the precise histologic type because many mesenchymal neoplasms appear as smooth swellings with intact mucosa or nonspecific ulceration.

Because many lesions arise deep within the wall, sampling quality is decisive. When the mucosa is intact, standard biopsies may be nondiagnostic; in such cases, endoscopic ultrasonography defines the layer of origin, the extraluminal component and relationships with mediastinal structures and permits targeted fine-needle aspiration or core-needle biopsy. If ulceration is present, multiple deep biopsies may be sufficient, but the strategy must always aim to obtain representative tissue for immunohistochemistry and, when necessary, molecular analyses.

Definitive diagnosis is pathologic and requires a targeted immunohistochemical panel. In GISTs, demonstration of DOG1 and/or KIT strongly supports the diagnosis, whereas in leiomyosarcomas, expression of smooth-muscle markers and the absence of typical GIST markers are key findings. In synovial sarcoma, molecular confirmation of the SS18-SSX rearrangement is often decisive when morphology is ambiguous. In parallel, the differential diagnosis must include common benign lesions, neuroendocrine tumors, undifferentiated carcinomas and other mediastinal neoplasms that may mimic an esophageal mass.

Staging and assessment of resectability require high-quality imaging. Contrast-enhanced CT of the chest and abdomen is the basis for evaluating local extent, lymph nodes and metastases; 18F-FDG PET may be useful for high-grade histologies and in selected settings to identify distant disease and guide biopsy of suspicious lesions. Bronchoscopy and otolaryngologic evaluation may be considered when the lesion is proximal or airway involvement is suspected, whereas preoperative nutritional and functional assessment is an integral part of treatment planning.

In summary, diagnosis is based on endoscopy and adequate sampling, endoscopic ultrasonography when required to obtain deep tissue, targeted immunohistochemistry and molecular profiling for classification, and comprehensive imaging to define extent, resectability and the multimodal treatment strategy.

Staging of primary esophageal sarcomas is complex because no single system is universally applicable to all histologies at this site. TNM systems used for esophageal carcinomas cannot be transferred to sarcomas because their biology, dissemination patterns and prognostic determinants differ. In clinical practice, assessment of extent must therefore be based on an accurate description of local invasion, resectability, lymph-node involvement when present and distant metastases, together with histologic features such as grade, necrosis and mitotic index.

To communicate disease extent clearly and guide treatment decisions, a pragmatic stratification distinguishing disease confined to the primary site from locally advanced or metastatic disease is useful. This approach does not replace an official system but provides a shared language among the endoscopist, surgeon, medical oncologist, radiation oncologist and pathologist, particularly when the available data derive from limited experience.

Practical assessment of disease extent in esophageal sarcomas

• Localized disease: tumor confined to the esophageal wall, with no evidence of distant metastases and potentially resectable.
• Locally advanced disease: extension to adjacent structures or technical conditions that make safe resection unrealistic, with or without suspicious lymph nodes but without distant metastases.
• Metastatic disease: visceral or extraregional metastases documented radiologically or histologically.

In esophageal GISTs, prognosis is strongly influenced not only by anatomic extent but also by biological and quantitative parameters. Tumor size, mitotic index, the presence of tumor rupture and the mutational profile affect recurrence risk and drug response. Because the esophageal site is rare, interpretation must be cautious and contextualized, but the risk-stratification principles used for gastrointestinal GISTs remain fundamental in practice.

Prognostic determinants of particular relevance in esophageal GIST

• Size of the lesion and its relationship with critical mediastinal structures, which affect resectability and rupture risk.
• Mitotic index and presence of necrosis, which have prognostic significance and more frequently support treatment indications in high-risk profiles.
• Tumor rupture, whether intraoperative or spontaneous, which is associated with a high risk of dissemination and recurrence.
• Mutational profile, which influences sensitivity to imatinib and other inhibitors in advanced disease.

For other sarcomas, prognosis is mainly associated with histologic grade, the possibility of achieving complete resection with negative margins, the presence of metastases at diagnosis and response to systemic therapy. Rarity makes generalizable prognostic estimates difficult; consequently, standardized reporting of radiologic and pathologic findings and multidisciplinary discussion are essential for a realistic risk assessment and treatment selection.

Treatment of primary esophageal sarcomas is necessarily individualized and depends on histologic type, grade, extent and resectability, as well as the patient’s nutritional and functional status. Rarity requires the application of established principles for GISTs and soft-tissue sarcomas, adapted to the anatomic complexity of the esophagus and the risk of local complications that may rapidly impair nutrition and quality of life.

In localized, resectable disease, surgery is often the cornerstone. The objective is complete resection with negative margins while balancing oncologic radicality and functional preservation. For esophageal GISTs, when technically feasible, limited resection or enucleation may be considered in selected cases, with extreme care to avoid rupture of the lesion; bulky masses or tumors at complex sites may require wider resection, up to esophagectomy, with reconstruction and dedicated nutritional support. For high-grade non-GIST sarcomas, radical resection is often more demanding, and margin definition must be discussed with the pathologist and sarcoma team because infiltrative biology may make truly conservative surgery difficult.

Systemic therapy varies by subtype. In GISTs, tyrosine kinase inhibitors are a mainstay in advanced disease and also have a role in selected resectable settings, both as preoperative treatment to reduce tumor volume and facilitate a more function-preserving resection and as postoperative treatment in high-risk situations. Drug selection and predicted efficacy depend on the mutational profile, making molecular characterization particularly important when systemic treatment is planned. In non-GIST sarcomas, chemotherapy may be used in neoadjuvant, adjuvant or palliative settings according to grade, risk and subtype, often with anthracycline-based regimens and, in selected variants, ifosfamide or other specific regimens.

Radiotherapy may be considered to improve local control in high-grade sarcomas or when margins are at risk, but its application at the esophageal site requires caution because of toxicity to the mediastinum, lungs and heart and should be planned using advanced conformal techniques. In metastatic or unresectable disease, treatment aims to control disease and symptoms through appropriate systemic strategies and, when necessary, endoscopic or radiotherapeutic interventions to restore transit and control bleeding.

Treatment objectives and strategies according to clinical context

• Localized disease: complete resection when feasible, with planning centered on margins and functional preservation; in GISTs, assessment of risk and the potential role of perioperative targeted therapy.
• Locally advanced disease: multimodal approach with possible systemic therapy to reduce tumor volume and reassess resectability; selective radiotherapy for local control in high-risk cases.
• Metastatic disease: systemic therapy guided by histologic type and biology; in GISTs, targeted therapy according to the mutational profile; in non-GIST sarcomas, chemotherapy and, in selected cases, targeted agents according to established indications.
• Impaired transit or bleeding: endoscopic procedures, enteral or parenteral nutrition and symptom control to permit continuity of treatment.

In every setting, nutritional management is a genuine therapeutic component rather than an ancillary measure. Dysphagia and weight loss may prevent delivery of complex treatments; therefore, dietary support, sarcopenia assessment and early adoption of enteral nutrition strategies when necessary improve treatment tolerance and reduce complications.

Follow-up after treatment of primary esophageal sarcomas must be tailored to histologic type, recurrence risk and the treatment performed because no universally standardized protocols specific to this site are available. In general, surveillance combines clinical assessment, nutritional monitoring and periodic imaging to detect locoregional recurrence or metastases at a stage when therapeutic intervention may be more effective.

In patients treated surgically with curative intent, the first few years carry the greatest risk and require closer monitoring. Clinical evaluation should assess dysphagia, regurgitation, pain, respiratory symptoms caused by aspiration, signs of bleeding and weight changes. Imaging with contrast-enhanced CT of the chest and abdomen provides a practical basis for surveillance, with intervals adjusted according to risk and histologic type; in selected subtypes or when findings are uncertain, PET may help clarify equivocal abnormalities or provide complete restaging.

Endoscopy is not necessarily required at regular intervals in every case, but it is indicated when suggestive symptoms develop or when anastomotic strictures, intraluminal recurrence or complications such as ulceration and bleeding must be evaluated. In GISTs treated with targeted therapy or followed after resection, instrumental surveillance is closely linked to the probability of recurrence estimated from clinicopathologic features and the biological profile of the disease.

In patients receiving systemic treatment for advanced disease, follow-up focuses on response, toxicity and preservation of alimentary function. The frequency of assessments is adjusted according to the treatment regimen and clinical stability, with particular attention to nutritional complications and drug-specific toxicities that may require timely intervention to prevent prolonged treatment interruptions.

Long-term quality-of-life considerations in primary esophageal sarcomas depend on the interaction among the anatomic and functional sequelae of surgery, the effects of systemic therapies and the psychological impact of a rare diagnosis. Even when disease control is achieved, residual dysphagia, fear of recurrence and the need for surveillance may substantially affect daily activities and perceived well-being.

After esophageal resections, especially when esophagectomy with reconstruction has been required, transit disorders, early satiety, reflux, nocturnal cough and aspiration risk may persist, requiring stable dietary adaptations. Nutritional rehabilitation with small, frequent meals, attention to food consistency and ongoing dietetic support reduce complications and improve autonomy. In some patients, management of anastomotic strictures with endoscopic dilations or temporary use of enteral support may be essential to maintain adequate intake.

Systemic therapies may leave prolonged sequelae. In GISTs, long-term targeted therapy may cause chronic adverse effects that affect energy, exercise tolerance and occupational activity. In sarcomas treated with chemotherapy, fatigue, neuropathies, reduced physical capacity and mood changes may persist beyond the end of treatment cycles, making rehabilitation and targeted monitoring of cardiovascular and metabolic risk factors useful when relevant to the treatment received.

The psychological dimension is amplified by rarity. Uncertainty related to limited evidence and the perception of less standardized care pathways may increase stress and somatic hypervigilance. Psycho-oncological support and clear communication about the rationale for follow-up, together with a stable multidisciplinary network, improve adaptation and promote more durable functional recovery over time.

Complications of primary esophageal sarcomas may result from local progression, systemic dissemination and the effects of treatment. Locally, the most typical complication is worsening dysphagia progressing to obstruction, with malnutrition and dehydration. Ulceration may cause bleeding, anemia and, more rarely, acute hemorrhage. In locally advanced disease, invasion of mediastinal structures may lead to fistulas, recurrent respiratory infections and rapid deterioration of the patient’s general condition.

Metastatic disease may cause organ failure according to the site of spread, with hepatic or pulmonary impairment and worsening performance status. Cancer cachexia and sarcopenia are cross-cutting complications, particularly relevant in a region where disease compromises nutrition, and require an early, structured approach to nutritional support and symptom control.

Surgical complications include dehiscence, anastomotic fistulas, strictures, infections and functional transit disorders with aspiration. Endoscopic procedures carry a risk of bleeding and perforation, especially when the wall is infiltrated or ulcerated. Prevention of complications relies on preoperative optimization, nutritional support, aspiration-risk management and close postoperative monitoring.

• Tyrosine kinase inhibitor toxicity in GISTs: edema, diarrhea, nausea, fatigue, cutaneous toxicity and hepatotoxicity, requiring laboratory monitoring and proactive management.
• Chemotherapy toxicity in non-GIST sarcomas: myelosuppression, mucositis, nausea, anthracycline-related cardiotoxicity and nephrotoxicity or neurotoxicity from specific agents, according to the regimens used.
• Toxicity from mediastinal radiotherapy when used: esophagitis, stenosis, radiation pneumonitis and late effects on cardiopulmonary structures.

Management of complications requires continuous multidisciplinary integration. Nutritional stabilization, pain control, aspiration prevention and timely access to palliative endoscopic or radiotherapeutic procedures are central to preserving quality of life and continuity of treatment; in advanced disease, early integration of palliative care facilitates more effective symptom control and reduces avoidable hospitalizations.